Business
Equillium Announces Publication of Abstract for the Annual Congress of the European Hematology Association
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that the European Hematology Association (EHA) has published an abstract highlighting the Phase 3 EQUATOR study in first-line acute graft-versus-host disease (aGVHD).\n\n\n\nTitle:\n\n\n\n\nEQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE\n\n\n\n\n\nAbstract Code:\n\n\n\n\nPB2196\n\n\n\n\n\nAuthor:\n\n\n\n\nJohn Koreth, associate professor of Medicine, Harvard Medical School, et. al.\n\n\n\n\nThe abstract discusses acute graft-versus-host disease (aGVHD) being a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplant (allo-HSCT) and that there is no approved first-line treatment, where corticosteroids remain standard of care. Itolizumab, a humanized IgG1 monoclonal antibody that binds CD6 and blocks interaction with activated leukocyte cell adhesion molecule (ALCAM) to inhibit T effector cell activity and trafficking to target organs, represents a promising therapeutic approach to treat aGVHD, as suggested by safety and efficacy results from the Phase 1b EQUATE study (NCT03763318). These results and benefit-risk profile led to the currently enrolling Phase 3 EQUATOR study, a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of itolizumab in combination with corticosteroids for the treatment of first-line aGVHD.\n\nFor more information and access to the abstract, visit the EHA Open Access Library.\n\nAbout the EQUATOR Study\n\nThe Phase 3, randomized, double-blind, placebo-controlled multicenter study (NCT05263999) will compare the efficacy and safety of IV administered itolizumab versus placebo (randomized 1:1) as a first-line therapy in up to 200 adult and adolescent patients with Grade III-IV aGVHD, or Grade II aGVHD with lower GI involvement, in combination with high doses of corticosteroids, the current standard of care. The primary study endpoint is complete response rate at Day 29; key secondary endpoints include overall response rate at Day 29 and durability of compl...